Cargando…
A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer
Platinum is recommended in combination with gemcitabine in the treatment of metastatic triple-negative breast cancer (mTNBC). We conduct a randomized phase 3, controlled, open-label trial to compare nab-paclitaxel/cisplatin (AP) with gemcitabine/cisplatin (GP) in mTNBC patients (ClinicalTrials.gov N...
Autores principales: | Wang, Biyun, Sun, Tao, Zhao, Yannan, Wang, Shusen, Zhang, Jian, Wang, Zhonghua, Teng, Yue-E, Cai, Li, Yan, Min, Wang, Xiaojia, Jiang, Zefei, Pan, Yueyin, Luo, Jianfeng, Shao, Zhimin, Wu, Jiong, Guo, Xiaomao, Hu, Xichun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276725/ https://www.ncbi.nlm.nih.gov/pubmed/35821019 http://dx.doi.org/10.1038/s41467-022-31704-7 |
Ejemplares similares
-
Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer
por: Li, Yi, et al.
Publicado: (2019) -
Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial
por: Zhao, Yannan, et al.
Publicado: (2018) -
Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer
por: Sun, Si, et al.
Publicado: (2014) -
Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
por: Xie, Yizhao, et al.
Publicado: (2021) -
Dendrimers Bind Antioxidant Polyphenols and cisPlatin Drug
por: Abderrezak, Amine, et al.
Publicado: (2012)